Ards, COVID-19, SARS-CoV2 Infection, Ventilator Associated Pneumonia
Conditions
Keywords
Intensive care Unit, multidrug resistance, COVID 19 ARDS, ventilator associated pneumonia, SARS-CoV2 Infection
Brief summary
In December 2019, a new pandemic emerged, the COVID-19 disease caused by a SARS-Cov-2 virus. One of the most common symptoms of COVID-19 is mainly respiratory failure and patients requires assistance by mechanical ventilation. Ventilator-associated pneumonia (VAP) is a risk of this assistance. Since the beginning of the pandemic, Standard of care have evolved with new data. The prevalence of these VAPs seems significantly higher in the population of patients with ARDS COVID-19 (40-50%) and their ecology seems to have evolved over time, particularly in terms of bacterial resistance. Investigators want to describe and compare this evolution of bacterial and fungal ecology as well as identify potential risk factors that may be associated with these changes in ecology during different waves.
Interventions
None listed
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Positive SARS-Cov-2 polymerase chain reaction (PCR) * healthcare associated pneumonia
Exclusion criteria
: Patient opposition to participate to the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VAP ecological difference between the first and second waves of COVID | January 2020 to January 2021 | Proportion of patients admitted to critical care with documented multidrug-resistant bacteria (MDR) VAP in Covid-19 wave 1 and 2 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| duration of mechanical ventilation | Day 28 | Number of days under mechanical ventilations |
| number of days of organ failure | Day 28 | number of days between first organ failure and no organ failure (discharge from intensive care) |
| Mortality | Day 28 | proportion of patients deceased at day 28 |
| proportion of fungal co-infections | January 2020 to January 2021 | Comparison of the proportion of patients with a fungal infection during the 1st and 2nd wave |
| probabilistic antibiotic therapy at admission | Day 1 | probabilistic antibiotic therapy prescribed at admission |
| antiviral treatment | Day 28 | proportion of patients treated with antiviral treatment |
| proportion of patients treated with corticosteroid therapy | Day 28 | proportion of patients treated with corticosteroid therapy |
Countries
France
Outcome results
None listed